This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Company type | Public |
---|---|
Industry | Medical equipment |
Founded | 1931 |
Founder | Donald Baxter |
Headquarters | Deerfield, Illinois, U.S. |
Key people | José E. Almeida (chairman & CEO) Jay Saccaro (CFO) |
Products | Medical supplies to treat haemophilia and kidney disease and provide intravenous therapy |
Revenue | US$14.81 billion (2023) |
US$380 million (2023) | |
US$2.663 billion (2023) | |
Total assets | US$28.28 billion (2023) |
Total equity | US$8.468 billion (2023) |
Number of employees | c. 60,000 (2023) |
Website | baxter |
Footnotes / references [1] |
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.[2]
The company primarily focuses on products to treat kidney disease, and other chronic and acute medical conditions. The company had 2017 sales of $10.6 billion, across two businesses: BioScience and Medical Products. Baxter's BioScience business produces recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions; products for regenerative medicine, and vaccines. Baxter's Medical Products business produces intravenous products and other products used in the delivery of fluids and drugs to patients; inhalational anaesthetics; contract manufacturing services; and products to treat end-stage kidney disease, or irreversible kidney failure, including products for peritoneal dialysis and hemodialysis.[3]